Lichen Planopilaris Linked to Elevated Risk of Autoimmune, Skin, and Heart Conditions: Meta-Analysis

USA: A comprehensive review and meta-analysis published in the International Journal of Dermatology has revealed that lichen planopilaris (LPP)-a rare, scarring form of alopecia—is significantly linked to a range of comorbid medical conditions, especially autoimmune, dermatologic, and cardiometabolic disorders.

Dr. Maryanne M. Senna and colleagues from the Department of Dermatology at Harvard Medical School, Boston, USA, conducted the study. Their goal was to clarify the associations between LPP and various systemic illnesses, an area previously marked by inconsistent findings.

To provide a clearer understanding, the team performed a systematic review and meta-analysis adhering to PRISMA guidelines. Researchers examined data from multiple databases, including PubMed/MEDLINE, EMBASE, the Cochrane Library, and Web of Science, up until December 25, 2023. Of the 2,535 studies initially screened, 59 met the inclusion criteria, covering a total of 15,178 patients diagnosed with LPP and over 64 million non-LPP controls.

The researchers reported the following findings:

  • Individuals with LPP had significantly higher odds of developing lichen planus (OR 15.78).
  • The risk of psoriasis is elevated among LPP patients (OR 3.55).
  • Rosacea was more common in those with LPP (OR 3.15).
  • LPP was associated with a higher risk of melanoma (OR 3.11).
  • There was an increased risk of cutaneous squamous cell carcinoma in LPP patients (OR 3.04).
  • Systemic lupus erythematosus was more frequently seen in individuals with LPP (OR 3.06).
  • The odds of having vitiligo were higher in LPP patients (OR 2.89).
  • Rheumatoid arthritis was more common among those with LPP (OR 1.50).
  • Hypothyroidism showed a significant association with LPP (OR 1.48).
  • Thyroiditis was also more prevalent in LPP patients (OR 1.26).
  • LPP patients were more likely to have coronary artery disease (OR 1.66).
  • Iron deficiency anemia was slightly more common among LPP patients (OR 1.18).

The authors emphasized that these associations emphasize the need for heightened clinical awareness when managing individuals with LPP. “Our findings suggest that LPP is not merely a localized scalp disorder but may reflect broader systemic immune dysfunction,” the authors noted. They advocated for clinicians to consider comorbidity screening as part of routine care for LPP patients.

Despite the robust methodology, the authors acknowledged the variability in study designs and populations across the included research as a limitation. They called for future studies to better understand the biological mechanisms driving these associations and to help define guidelines for screening and long-term monitoring.

The authors concluded, “The meta-analysis positions LPP as a dermatological condition with important systemic implications, highlighting the importance of multidisciplinary care and early comorbidity detection to improve patient outcomes.”

Reference:

Chen, C., Ogbutor, C., Bae, S., Spencer, C., Kelley, K. J., & Senna, M. M. Comorbidities Associated With Lichen Planopilaris: A Systematic Review and Meta-Analysis. International Journal of Dermatology. https://doi.org/10.1111/ijd.17925

Powered by WPeMatico

New urine-based tumor DNA test may help personalize bladder cancer treatment: Study

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for recurrence after treatment.

This study analyzed utDNA from patients in the SWOG S1605 trial, who were treated with atezolizumab, an immunotherapy drug. Researchers used the UroAmp test to examine urine samples from 89 patients at the start of treatment and from 77 patients three months later. The goal was to see if utDNA could help identify which bladder cancer patients are most likely to respond to immunotherapy.

“This approach could help improve patient care by guiding more effective treatments and supporting more personalized plans,” said Robert Svatek, MD, MSCI, professor and chair of urology at the Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio). “It means we may be able to tailor therapy sooner, reduce unnecessary delays and help patients avoid major surgery without compromising the quality of their care.”

A nationally recognized urologic oncologist with the Mays Cancer Center at UT Health San Antonio, Svatek is the leading expert in bladder cancer and a member of SWOG, also known as Southwest Oncology Group. SWOG is part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN) and one of the five leading cancer clinical trial groups in the United States.

The SWOG S1605 study was a phase 2 clinical trial testing atezolizumab in patients with high-risk bladder cancer that didn’t respond to BCG (Bacillus Calmette-Guérin) treatment, the main immunotherapy to treat early-stage bladder cancer.

Samples were collected from participants before treatment and again three months later. Researchers used the UroAmp assay, a non-invasive urine test that detects bladder cancer–related mutations, to analyze utDNA and generate a genomic profile for each patient.

They found that utDNA levels were linked to how well patients responded after six months and how long they stayed cancer-free over 18 months. Patients with positive utDNA results were less likely to respond and more likely to have their cancer return.

According to the American Cancer Society, bladder cancer is the sixth most common cancer in the United States, with more than 83,000 new cases diagnosed annually. Of these cases, approximately 75% are non–muscle invasive, meaning the cancer has not yet invaded the bladder muscle.

Patients who don’t respond to immunotherapy may face the difficult decision of either continuing therapies that spare the bladder but carry high risks of recurrence or undergo major surgery that removes the bladder and profoundly impacts one’s quality of life.

This study offers new hope for patients with high-risk bladder cancer by showing that a urine-based DNA test can help predict who is more likely to benefit from immunotherapy. By identifying treatment response early, this approach could guide more personalized, bladder-preserving care and reduce the need for major surgery.

Reference:

Marie-Pier St-Laurent, Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Joshua J. Meeks, Vincent M. Caruso, Ceressa T. Ward, Brian C. Mazzarella, Kevin G. Phillips, Vincent T. Bicocca, Trevor G. Levin, Seth P. Lerner, Peter C. Black, Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer, European Urology, 2025, https://doi.org/10.1016/j.eururo.2025.03.023.

Powered by WPeMatico

Regular Sexual Activity May Reduce Vulvar Discomfort, pain and discomfort in perimenopausal and postmenopausal women : Study

Researchers have found in a new study that women aged 40 to 70 who engage in regular sexual activity may experience reduced vulvar pain, dryness, and irritation. Interestingly, orgasm and sexual satisfaction levels appear to remain unaffected by age, suggesting continued sexual engagement may support vaginal health without diminishing pleasure.

It’s no secret that women often become less interested in sex with age. However, orgasm and satisfaction have been shown to not decline significantly with age. A new study suggests regular sexual activity may limit vulvar pain, irritation, and dryness, which are all common reasons women have less sex as they get older. Results of the study are published online today in Menopause, the journal of The Menopause Society.

Estrogen deficiency during and after menopause may reduce the life expectancy of women and impair their quality of life through a condition called genitourinary syndrome of menopause (GSM). In 2014, GSM was defined as a collection of symptoms and signs associated with decreased estrogen and sex steroid levels. GSM includes genital, sexual and urinary symptoms-all of which can affect the frequency of sexual activity for women aged in their 40s to 70s.

In this new study involving more than 900 women aged 40 to 79 years, researchers sought to examine the association between sexual regularity and vulvovaginal-related problematic menopause symptoms. The vulva refers to the external female genitalia, and the vagina to the internal anatomy. Common problems experienced with menopause include itching, burning, pain, decreased lubrication, and changes in skin appearance.

Engaging in sexual activity in the past 3 months was defined as regular sexual activity, whereas engaging in sexual activity in the past year (but not in the past 3 months) was considered lower sexual activity. Not surprisingly, the researchers confirmed that the proportion of women having regular sexual activity decreased significantly with age, which aligns with the fact that Female Sexual Function Index scores for sexual desire, arousal, and lubrication also significantly decreased with age. The Female Sexual Function Index consists of 19 questions on female sexual function under six domains. Noteworthy, however, was that the scores for orgasm and satisfaction did not change with age.

Based on the results of the study, the researchers determined that some sexual functions and symptoms change with age but may be maintained in women who engage in more regular sexual activity. This study also revealed that women with regular sexual activity showed a low prevalence of GSM-related symptoms.

Study results are published in the article “Cross-sectional study of the association between regular sexual activity and sexual function and genitourinary syndrome of menopause-related symptoms.”

“The findings highlight the importance of diagnosing and treating GSM. Only 2.9% of the participants reported using hormone therapy. Local low-dose vaginal estrogen therapy is safe and highly effective at alleviating bothersome vulvovaginal symptoms contributing to pain and avoidance of intercourse. And although optimal sexual health is integral to overall well-being, it is also imperative to recognize the effect these symptoms can have on women who aren’t sexually active. Treatment should be offered to anyone with symptoms, whether engaging in sexual activity or not. Normalizing use of local low-dose estrogen therapy should be a thing,” says Dr. Monica Christmas, associate medical director for The Menopause Society.

Reference:

Yoshikazu Sato, Cross-sectional study of the association between regular sexual activity and sexual function and genitourinary syndrome of menopause-related symptoms, Menopause, DOI: 10.1097/GME.0000000000000002539.

Powered by WPeMatico

Integrating Innovation: Study explores Clinician Insights on Apps for Hypertensive Disorders of Pregnancy

Hypertensive disorders of pregnancy (HDP) significantly contribute to maternal morbidity and mortality in the U.S., which exhibits one of the highest maternal mortality rates among high-income countries. Approximately 10% of pregnancies are affected by forms of HDP such as chronic hypertension, preeclampsia, and gestational hypertension, leading to severe health risks for mothers and neonates. Home blood pressure monitoring (HBPM) is proposed as a solution to enhance care quality, providing timely and relevant data critical for informed clinical decisions regarding hospital admissions and treatments. A recent study investigates the viewpoints of clinicians and highlights the challenges encountered in implementing an app specifically designed for hypertensive disorders of pregnancy (HDP).

Clinician Perspectives on P-COACH

The exploration of clinicians’ perceptions regarding the integration of an HDP-specific app, P-COACH, revealed potential benefits but also highlighted significant challenges. Key insights were gathered through qualitative interviews with diverse clinicians who provided multifaceted views on the utility of such applications in managing HDP. Participants pointed out that HBPM could improve access to care, especially for underserved populations affected by socio-economic barriers and rural healthcare challenges. They recognized the unique motivation of pregnant individuals to engage in health-improving behaviors during this period, suggesting P-COACH could facilitate sustained hypertension management through empowerment and education.

Barriers to Home Blood Pressure Monitoring

However, concerns regarding affordability of BP monitoring equipment limited the accessibility of HBPM. The financial burden, coupled with the need for literacy-appropriate resources, poses barriers to successful implementation. Clinicians highlighted the need for streamlined workflows and integration of HBPM data into electronic health records (EHRs) to reduce the administrative burden on healthcare providers and focus more on patient care. The unawareness of critical BP readings could put patients at risk, emphasizing the necessity for defined protocols and clear roles among care team members to interpret and act on BP data accurately.

Considerations for P-COACH Implementation

Implementing P-COACH successfully requires addressing barriers including liability issues associated with patient-generated data oversight, as well as ensuring providers receive adequate training and resources. Participants underscored the importance of developing an understanding of individual patient risks to tailor alerts meaningfully and responsively. Despite the promising features of P-COACH in enhancing communication, continuity of care, and mitigating complications postpartum, potential limitations include the need for broader studies encompassing varied healthcare settings and patient perspectives. Engaging diverse populations and ensuring affordable access to technology remain critical for equitably addressing HDP challenges and improving maternal health outcomes.

Key Points

– -Maternal Morbidity and Mortality-: Hypertensive disorders of pregnancy (HDP) are significant contributors to maternal morbidity and mortality in the U.S., with around 10% of pregnancies affected by conditions like chronic hypertension, preeclampsia, and gestational hypertension. These disorders are associated with severe health risks for mothers and neonates, highlighting the need for effective management and intervention strategies.

– -Home Blood Pressure Monitoring (HBPM) Benefits-: Incorporating HBPM into prenatal care can enhance the quality of healthcare delivery by providing timely, relevant blood pressure data, which are crucial for informed clinical decisions regarding hospital admissions and treatments. This method addresses access disparities, particularly for underserved demographics affected by socio-economic challenges and rural healthcare limitations.

– -Clinician Insights on P-COACH-: Qualitative interviews with clinicians reveal that while there are potential advantages in using the HDP-specific app P-COACH, there are also significant hurdles. Clinicians recognize the app’s potential to motivate pregnant individuals to engage in health-improving behaviors and aid sustained management of hypertension.

– -Barriers to Effective HBPM Implementation-: Concerns regarding the affordability of blood pressure monitoring equipment, alongside the need for literacy-appropriate resources, hinder the successful implementation of HBPM. Clinical feedback indicates that streamlined workflows and incorporation of HBPM data in electronic health records (EHRs) are necessary to alleviate administrative burdens and concentrate on patient care.

– -P-COACH Implementation Considerations-: Effective implementation of P-COACH necessitates addressing various barriers, such as liability issues related to patient-generated data and ensuring healthcare providers are adequately trained. Tailoring alerts based on individual risk profiles is emphasized for responsive and meaningful patient engagement.

– -Need for Broader Studies and Engagement-: While P-COACH offers promising features for improving communication and continuity of care, limitations such as the need for more extensive studies across diverse healthcare settings and patient viewpoints persist. Ensuring affordable access to technology and engaging varied patient populations are critical to equitably confront HDP challenges and enhance maternal health outcomes.

Reference –

Shannon Canfield et al. (2025). Using RE-AIM To Inform The Adaptation Of A Clinical Decision Support Application For Hypertension Disorders Of Pregnancy: A Qualitative Study Of Provider Perspectives. *BMC Pregnancy And Childbirth*, 25. https://doi.org/10.1186/s12884-025-07632-x.

Powered by WPeMatico

Acute Cognitive Symptoms, Mental Health History Predict Long-Term Concussion Effects in Adults: Meta-Analysis

Canada: A recent systematic review and meta-analysis have identified several key factors that increase the likelihood of adults experiencing persistent symptoms after a concussion (PSAC), even months after a mild traumatic brain injury (mTBI). The findings, published in JAMA Network Open, are from a study led by Dr. Samantha J. McIntosh and colleagues from the Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta, Canada.

Concussion symptoms are typically expected to resolve within weeks, yet nearly 30% of individuals with mTBI continue to experience lingering effects well beyond the initial injury. The new analysis highlights which early clinical signs may help clinicians better predict long-term outcomes in these patients.

Researchers analyzed data from 15 studies involving over 592,000 adults who had sustained a concussion. Participants’ average age was 29.3 years, with ages ranging from 16 to 89 years. The meta-analysis focused on identifying acute clinical factors—reported within one month of injury—that were associated with ongoing symptoms at 1, 3, and 6 months post-concussion.

The key findings were as follows:

  • Difficulty concentrating soon after the injury emerged as the strongest predictor of persistent post-concussion symptoms (PSAC) across all time points.
  • Individuals with a history of anxiety, depression, or sleep disorders were at a significantly higher risk of developing long-term post-concussion symptoms.
  • Clinical signs at the time of injury, such as loss of consciousness and amnesia, were also linked to an increased likelihood of PSAC.
  • Concentration difficulties more than tripled the odds of experiencing persistent symptoms.
  • Pre-existing mental health conditions or sleep disorders nearly doubled the risk of long-term post-concussion symptoms.
  • These associations remained consistent whether symptoms persisted at one month, three months, or six months after the injury.
  • Older age was investigated as a possible risk factor but did not show a strong association with PSAC, partly due to inconsistent reporting in the analyzed studies.
  • The review found significant variability in how PSAC is defined and diagnosed across studies, contributing to challenges in comparing results and high heterogeneity in the findings.

Importantly, the study focused on individuals without intracranial abnormalities, meaning its conclusions may differ from prior research involving broader populations.

Despite these limitations, the authors believe that evaluating specific acute symptoms—particularly cognitive difficulties and a history of mental health or sleep disorders—can greatly enhance clinical decision-making and inform prognosis for patients with mTBI. They recommend that future research should further refine predictive models for PSAC and explore how combinations of risk factors may help guide personalized care.

The authors concluded, “By identifying at-risk patients early, clinicians may be better equipped to target interventions and potentially mitigate the long-term impact of concussion.”

Reference:

McIntosh SJ, Vergeer MH, Galarneau J, Eliason PH, Debert CT. Factors Associated With Persisting Symptoms After Concussion in Adults With Mild TBI: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2025;8(6):e2516619. doi:10.1001/jamanetworkopen.2025.16619

Powered by WPeMatico

Prophylactic Antibiotics Reduce SSI Only in Open Pyloromyotomy Cases

Researchers identified that the routine use of prophylactic antibiotics in infants who are having pyloromyotomy might not always prevent surgical site infections (SSI) but could reduce infection incidence significantly in those that have open surgical repair. The study was published in the journal of Annals of Surgery by Kerri A. and colleagues.

To explain these variations in practice, data from 6,093 infants who had pyloromyotomy between January 2021 and December 2023 at 148 hospitals in the NSQIP-Pediatric program were analyzed. The researchers contrasted outcomes among patients who received prophylactic antibiotics with those who did not, using patient-level propensity matching and mixed-effects models.

The study team utilized a strong multicenter design to facilitate generalizability of findings. Propensity-matched comparisons that controlled for patient factors and hospital clusters were utilized to contrast infection outcomes. The study also had a hospital-level analysis to examine if institutional rates of prophylaxis were related to better SSI rates. Subgroup analyses were performed to explore separately infants that received laparoscopic versus open pyloromyotomy and to give a detailed insight regarding surgical approach effect on outcomes.

Key Findings

  • The cohort of 6,093 infants had 46.6% who were given prophylactic antibiotics.

  • Of the matched cohorts (2,591 per group), SSI was found in 1.6% (38 infants) of the no-prophylaxis group and 1.1% (28 infants) in the prophylaxis group (adjusted odds ratio [aOR]: 0.61; 95% CI: 0.37–1.01), hinting at a lack of overall statistically significant benefit.

  • Institutional usage of antibiotics wasn’t associated with decreased SSI rates (Spearman ρ = 0.11, P = 0.13), which means that increased prophylaxis use at the hospital level didn’t result in improved outcomes.

Laparoscopic pyloromyotomy subgroup:

  • SSI rate: 1.1% both in prophylaxis and non-prophylaxis groups, OR: 0.96 (95% CI: 0.55–1.69), which means no benefit from prophylaxis

Open pyloromyotomy subgroup:

  • SSI rate: 5.1% in no-prophylaxis group vs 1.9% in prophylaxis group, OR: 0.36 (95% CI: 0.14–0.93), demonstrating marked reduction in infections with antibiotics

This multicenter analysis offers important information regarding the efficacy of antibiotic prophylaxis in infant pyloromyotomy. These results warrant a selective approach to prophylaxis, reserving antibiotics for more susceptible open cases over a broad blanket application for all patients. This individualized approach may enhance outcomes with less unnecessary antibiotic use in infants.

Reference:

McKie KA, Moturu A, Graham DA, Coleman M, Huang R, Grant C, Saito JM, Hall BL, Cina RA, Newland JG, Ko C, Rangel SJ. Prophylactic Antibiotic use and Outcomes in Infants Undergoing Pyloromyotomy: A Multicenter Propensity Matched Cohort Analysis. Ann Surg. 2025 Jun 20. doi: 10.1097/SLA.0000000000006806. Epub ahead of print. PMID: 40539274.

Powered by WPeMatico

Probiotics Show Benefits in Periodontitis Management, reveals meta-analysis

Researchers have found in an umbrella meta-analysis that probiotics supplementation may positively influence periodontal health by improving Bleeding on Probing (BOP) and Clinical Attachment Level (CAL) in individuals undergoing treatment for periodontitis.

Probiotics supplementation has many beneficial impacts on periodontitis outcomes. This umbrella meta-analysis evaluated the effectiveness of probiotics in treating periodontitis, focusing on primary outcome measures, including reductions in probing pocket depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), plaque index (PI), gingival index (GI), and PDD reduction in medium and deep pockets. All meta-analyses evaluating the impact of probiotics supplementation on periodontitis outcomes were considered eligible. A random-effects model was employed to estimate the pooled results. Subgroup and sensitivity analyses were conducted. The quality of the studies was evaluated using the AMSTAR2 tool. Overall, 19 meta-analyses with 67 data sets were included in this umbrella review. Our findings indicated that probiotics supplementation significantly decreased BOP (effect size [ES]: −8.20; 95% CI: −15.10 to −1.31; P = .02) and CAL after sensitivity analysis (ES: −0.52; 95% CI: −0.75 to −0.28; P < .05). No other significant effect was observed on PPD, PI, GI, or PDD reduction in medium and deep pockets. This umbrella meta-analysis found that, during their treatment process, probiotics supplementation may positively affect BOP and CAL in people with periodontitis.

Reference:

Junfeng Tan, Dan Zhang, Li Cheng, Ning Liu, Mehrdad Jamali, Helen Jamloo, Rosana Farjaminejad, Changjiang Lei, Ahmad Saedisomeolia, Abdolreza Jamilian, The Impacts of Probiotics Supplementation on the Treatment of Periodontitis: An Umbrella Meta-Analysis, Nutrition Reviews, 2025;, nuae190, https://doi.org/10.1093/nutrit/nuae190

Keywords:

Probiotics, Show, Benefits, Periodontitis, Management, reveals, meta-analysis, probiotics, periodontitis, oral flora, umbrella meta-analysis, Junfeng Tan, Dan Zhang, Li Cheng, Ning Liu, Mehrdad Jamali, Helen Jamloo, Rosana Farjaminejad, Changjiang Lei, Ahmad Saedisomeolia, Abdolreza Jamilian, Nutrition Reviews

Powered by WPeMatico

A new blood test may detect leukemia risk and replace bone marrow sampling

What if a blood test could reveal the pace of our aging – and the diseases that may lie ahead? The labs of Profs. Liran Shlush and Amos Tanay at the Weizmann Institute of Science have been conducting in-depth studies into the biology of blood to better understand the aging process and why some people become more susceptible to disease over the years. Their research teams, made up of physicians, biologists and data scientists, have been tracking changes in the blood-forming stem cells, including the emergence of genetic changes in these cells in about one-third of people over the age of 40. These changes not only increase the risk of blood cancers such as leukemia, but have also been linked to heart disease, diabetes and other age-related conditions.

In a new study published today (Friday) in Nature Medicine – just days after their labs were severely damaged in an Iranian missile attack – Shlush and Tanay present findings that may lead to an innovative blood test for detecting a person’s risk of developing leukemia. This test may potentially replace the invasive diagnostic procedure of bone marrow sampling.

The study focused on myelodysplastic syndrome (MDS), an age-related condition in which blood stem cells fail to properly mature into functional blood cells. Diagnosing MDS and assessing its severity is crucial, as it can lead to severe anemia and may progress to acute myeloid leukemia, one of the most common blood cancers in adults. Until now, diagnosis has relied on bone marrow sampling, a procedure that requires local anesthesia and can cause discomfort or pain.

In the new study, a research team led by Dr. Nili Furer, Nimrod Rappoport and Oren Milman, in collaboration with physicians and researchers in Israel and the United States, showed that rare blood stem cells – which occasionally exit the bone marrow and enter the bloodstream – carry diagnostic information about MDS. The researchers demonstrated that with a simple blood test and advanced single-cell genetic sequencing, it is possible to identify early signs of the syndrome and even assess a person’s risk of developing blood cancer.

The researchers also discovered that the migrating stem cells can serve as a clock for our chronological age, and that in males, their population changes earlier than in women in a way that increases the risk of cancer. This finding may explain the higher prevalence of blood cancers among men. The scientists believe that using the test to diagnose MDS and leukemia is only the beginning, and that in the future it could be applied to a range of other blood-related disorders. The current findings are already being tested in a large-scale clinical trial at several medical centers around the world.

In addition to his laboratory research, Shlush is also a senior physician at Assuta Medical Center in Ashdod and at Maccabi Healthcare Services, and he heads the newly established Miriam and Aaron Gutwirth Medical School at the Weizmann Institute. The school was founded to address the emerging needs and challenges of the worlds of medicine and research and to bridge, as much as possible, the gap between today’s science and tomorrow’s medicine. Unlike existing programs around the world that combine medicine with research, the new program is expected to unify and intertwine the clinical and research components. The school is scheduled to open its doors for the first time this coming October and aims to train the next generation of physician-scientists.

Reference:

Furer, N., Rappoport, N., Milman, O. et al. A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics. Nat Med (2025). https://doi.org/10.1038/s41591-025-03716-5.

Powered by WPeMatico

UP NEET MDS 2025 admissions- Internship deadline extended

Uttar Pradesh- Through a notice, Uttar Pradesh Director General, Medical Education & Training (UPDGME) has released important information regarding the eligibility for UP National Eligibility and Entrance-Master of Dental Surgery (NEET MDS) Counselling for the academic year 2025.

As per the notice, the internship deadline has been extended for the Eligibility of the candidates who are willing to participate in the UP NEET MDS counselling 2025. According to the notice, “Only those candidates will be eligible to participate in the counselling of NEET MDS 2025, whose internship is being completed on June  31, 2025”.

Also Read: UP DGME Releases NEET MDS 2025 Seat Matrix: 700 Seats Vacant Across 25 Dental Colleges

Earlier, the deadline for March 31st 2025.

The NEET MDS 2025 1st round of Online Counselling will end on 14th July 2025. Below is the detailed schedule-

SCHEDULE

S.NO

DESCRIPTION

DATE & TIME

TOTAL DAYS

1

Date of online registration

01st July 2025 (From 11:00 AM) to 04th July 2025 (Till 11:00 AМ)

03 days

2

Date of depositing registration fee and security Fee

01st July 2025 (From 11:00 AM) to 04th July 2025 (Till 2:00 PM)

04 days

3

Date of declaration of merit list

04th July 2025

01 days

4

Date of online choice filling

04th July 2025 (From 5:00 PM) to 07th July 2025 (Till 5:00 PM )

03 days

5

Date of declaration of the result of seat allotment

08th July 2025

01 days

6

The date for downloading allotment letters and the admission process.

09th July 2025 to 12th July 2025 & 14th July 2025

05 days

Meanwhile, UPDGME has recently released the seat matrix for the National Eligibility and Entrance Test-Postgraduate (NEET PG) Counselling for the Master of Dental Courses (MDS) courses for the academic year 2025. On this, Medical Dialogues has reported that as per the seat matrix, a total of 700 seats are vacant across 25 dental Colleges of Uttar Pradesh.

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/updgme-293103.pdf

Powered by WPeMatico

Kerala MDS Admissions 2025 registrations open, Check out tuition fees at govt, private dental colleges

Kerala- The Commissioner for Entrance Examinations (CEE) Kerala is inviting allotment to Postgraduate (PG) Dental Master of Dental Surgery (MDS) Courses, Kerala for the academic year 2025. In this regard, CEE Kerala has issued a notification detailing the schedule, list of Colleges included in the Allotment, fees and other important details.

As per the notification, the activities related to the first phase of centralized allotment to Post Graduate Dental (MDS) Courses for the year 2025 have commenced. Therefore, for the first phase of allotment, candidates must register the online options on or before 06 July 2025, 11:59 PM.

Also Read: CEE Kerala Invites Applications for DNB Post Diploma Courses 2025, Check complete admission details

To register for the 1st phase of allotment, which is to be published by the CEE, candidates have to click ‘PG Dental 2025- Candidate Portal’ available on the official website of CEE Kerala and enter their Application Number and Password in order to access their home page. The candidates can register their options online by clicking the menu ‘Option Registration’ available in the home page. A security deposit / option registration fee of Rs. 10,000/- will have to be paid at the time of option registration. For SC/ST/OEC and other candidates who are eligible for fee concession, Rs 5000/- will also have to be paid as security deposit.

However, the registration fee once paid will not be allowed to change at any instance. The registration fee of those candidates who do not get allotment will be refunded after the completion of entire counseling process. The registration fee will be adjusted to the course fee if a candidate gets allotment. The registration fee of those candidates who do not join within the stipulated time after getting the allotment and those candidates who quit the seats after taking admission will be considered as penalty and will not be refunded.

In the second phase counseling, there is no facility for fresh option registration for the candidates. Only option confirmation/deletion/rearrangement of the existing valid options is possible. Option confirmation is compulsory to participate in the second phase of the allotment process.

Option registration will be available only to any new course/college added to the allotment process at this stage. If a candidate is allotted a seat in the first phase and joined the allotted seat, his/her higher options will be retained and all those options listed below the allotted option will automatically be deleted thus enabling only upgradation/retention of the same seat. After the first two phases of counseling, third/final phase counseling will start, which offers fresh option registration to candidates.

The conversion of seats if any will be carried out during the final phase of allotment. A fresh option registration fee will be implemented to all candidates, who register fresh options in the final phase. After the final phase allotment, if any vacancies exist or arise, those vacancies shall be filled through Stray vacancy filling allotment.

Meanwhile, candidates can give options as per their priority of the Course/College/Quota combinations in the option list. A candidate need only give options to a Course-College combination if he/she is sure to join the course and college, under the chosen quota, if allotted. Options registered online alone will be considered for allotment to the courses. Options sent to the Office of the Commissioner for Entrance Examinations via Post/Fax/Email will not be processed /considered for allotment to the courses.

Candidates who seek admission under Minority/NRI quota in Self Financing Dental Colleges shall have to register options online to the desired courses/colleges/quota, during the time of online option registration for first phase itself. The nativity/community/category claims (including Minority/NRI/In-service quota) made by the candidates in the online application will be rejected, if the required documents are not uploaded to the online application within the stipulated time.

The allotment to service quota seats will be conducted during the subsequent phases of allotment. However, those service quota candidates who wish to get allotment other than service quota seats should give options in this phase itself. Candidates who do not register Minority/NRI quota options, shall not be considered for allotment under Minority/NRI quota even if they are included in the respective category lists.

LIST OF COLLEGES INCLUDED IN THE ALLOTMENT

S.NO

COLLEGE NAME

TUITION FEES

GOVERNMENT DENTAL COLLEGES

1

Govt.Dental College, Kozhikode.

52100

2

Govt.Dental College, Kottayam.

52100

3

Govt.Dental College, Thiruvananthapuram

52100

SEF-FINANCING DENTAL COLLEGES

85 percent seats

10 percent seats

1

Annoor Dental College, Ernakulam.

850000

1500000

2

Sree Anjaneya Institute of Dental Sciences, Kozhikkode

850000

1500000

3

Educare Dental College, Malappuram.

850000

1500000

4

KMCT Dental College, Kozhikode.

850000

1500000

5

Mar Baselios Dental College, Ernakulam.

850000

1500000

6

MES Dental College, Malappuram.

850000

1500000

7

Malabar Dental College, Malappuram.

850000

1500000

8

Pushpagiri College of Dental Science, Thiruvalla.

850000

1500000

9

PMS College of Dental Science & Research Centre, Thiruvananthapuram

850000

1500000

10

PSM College of Dental Science& Research, Trichur.

850000

1500000

11

Royal Dental College, Palakkad.

850000

1500000

12

St. Gregorios Dental College, Ernakulam.

850000

1500000

13

Sri Sankara Dental College, Thiruvananthapuram.

850000

1500000

To view the notification, click the link below

https://medicaldialogues.in/pdf_upload/cee-kerala-begins-pg-dental-mds-2025-allotment-process-register-now-293124.pdf

Powered by WPeMatico